Horizon Pharma Stock Price, News & Analysis (NASDAQ:HZNP)

$13.89 -0.20 (-1.42 %)
(As of 02/20/2018 02:48 AM ET)
Previous Close$14.09
Today's Range$13.87 - $14.27
52-Week Range$9.45 - $17.69
Volume1.17 million shs
Average Volume1.71 million shs
Market Capitalization$2.28 billion
P/E Ratio-4.57
Dividend YieldN/A
Beta1.35

About Horizon Pharma (NASDAQ:HZNP)

Horizon Pharma logoHorizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:HZNP
CUSIP44047T10
Phone+353-1-7722100

Debt

Debt-to-Equity Ratio1.89%
Current Ratio1.64%
Quick Ratio1.52%

Price-To-Earnings

Trailing P/E Ratio-4.56907894736842
Forward P/E Ratio19.29
P/E Growth0.65

Sales & Book Value

Annual Sales$981.12 million
Price / Sales2.32
Cash Flow$3.11 per share
Price / Cash4.47
Book Value$7.84 per share
Price / Book1.77

Profitability

Trailing EPS($3.04)
Net Income$-166,830,000.00
Net Margins-45.28%
Return on Equity20.22%
Return on Assets5.35%

Miscellaneous

Employees1,050
Outstanding Shares163,890,000

Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions

What is Horizon Pharma's stock symbol?

Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP."

How will Horizon Pharma's stock buyback program work?

Horizon Pharma announced that its board has initiated a stock repurchase program on Sunday, June 4th 2017, which authorizes the company to repurchase 1,000% of outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.

How were Horizon Pharma's earnings last quarter?

Horizon Pharma PLC (NASDAQ:HZNP) announced its quarterly earnings data on Monday, November, 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.22 by $0.04. The biopharmaceutical company had revenue of $271.60 million for the quarter, compared to analysts' expectations of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. Horizon Pharma's revenue was up 30.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.70 earnings per share. View Horizon Pharma's Earnings History.

When will Horizon Pharma make its next earnings announcement?

Horizon Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Horizon Pharma.

Where is Horizon Pharma's stock going? Where will Horizon Pharma's stock price be in 2018?

11 brokerages have issued 1 year price objectives for Horizon Pharma's stock. Their forecasts range from $13.00 to $30.00. On average, they anticipate Horizon Pharma's stock price to reach $19.18 in the next year. View Analyst Ratings for Horizon Pharma.

What are Wall Street analysts saying about Horizon Pharma stock?

Here are some recent quotes from research analysts about Horizon Pharma stock:

  • 1. According to Zacks Investment Research, "Horizon has been focused on expanding its orphan drug business.The company has been quite active on the acquisition front over the past few quarters. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. Moreover, in Jun 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in the Europe, the Middle East and Africa regions to Chiesi Farmaceutici S.p.A. as the company focuses on higher-return businesses. Shares of the company have underperformed the industry. With the company’s efforts to expand Actimmune’s label suffered a setback, focus will be on Krystexxa’s performance. Stiff competition for drugs will also impact sales." (10/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "We are maintaining our Overweight rating and $17, 12 month PT for HZNP shares, but lowering our 2017 and 2018 EPS estimates because we have taken out some sales for the Raptor franchise now that Horizon has completed the sale of its EU marketing rights to Chiesi (Not Covered). We continue to expect Krystexxa sales to be impacted by the 340b program in 4Q17, which could prove conservative. Please see our note for details Potential HHS Delay Could Be Positive for HZNP’s Krystexxa Sales This Year. We expect orphan drug sales to increase 50% YOY which is in line with Horizon’s guidance, and rheumatology sales to increase 37% YOY, which is also roughly in line with Horizon’s guidance. Valuation. We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $17." (9/11/2017)
  • 3. Piper Jaffray Companies analysts commented, "We had the opportunity to travel with Horizon senior management in meetings with investors. We gained additional insight into Pennsaid 2% and Ravicti, and also came away with insights into management's latest thinking regarding M&A. Though there are undoubtedly some headwinds facing the primary care segment, we believe that this segment should be on largely stable footing over the long-term given HZNP's payer contracting efforts. That dynamic combined with continued strength from the rare disease segment points to a long-term EPS CAGR (2017-2022) in the mid-teens, and should translate into multiple expansion with a 2017E P/E currently at 7x. We reiterate our Overweight rating and are lowering our PT to $30 from $32 (see below for more details)." (3/24/2017)
  • 4. Guggenheim analysts commented, "HZNP reported a 4Q16 beat, underscoring our confidence that HZNP can continue to meet or exceed earnings expectations in '17+. Post 4Q16, we think that the peak sales potential of Pennsaid 2%, Procysbi, and Krystexxa are underappreciated, with additional earnings upside potentially coming from M&A as HZNP redeploys cash generated by its Primary Care ("PC") business into business development focused on orphan and rare disease indication medicines. While concerns remain over growth prospects for HZNP's PC business, Ravicti and Actimmune, these assets continue to generate meaningful cash to fuel HZNP's growth aspiration of $2B in sales by 2020." (2/27/2017)
  • 5. Mizuho analysts commented, "We are positive on HZNP ahead of the February 27 earnings call: We think the company may deliver a 4Q:16 earnings beat. We model 4Q:16 revenues of $325.4M and EPS of $0.57 relative to consensus $308.5M and $0.50 and implied guidance $309-$314M. Horizon has delivered strong beats in the past and we expect adjusted EBITDA to approach the higher end of the guidance range of $450-$460M. With respect to 2017 guidance, we fall below FactSet consensus estimates of $1,289.7M and $2.39 (we model $1,281.8M and $2.29), but note that Horizon may be able to beat this range via a combination of both price and volume growth, so guidance could come in stronger than expected. There is still significant uncertainty around business operation under the new PBM contracts, gross to net discounts, infrastructure needs, and the timing of anticipated volume growth. We therefore expect the focus of the call to be around these issues as well as on future business development targets and pipeline outlook." (2/22/2017)

Who are some of Horizon Pharma's key competitors?

Who are Horizon Pharma's key executives?

Horizon Pharma's management team includes the folowing people:

  • Timothy P. Walbert, Chairman of the Board, President, Chief Executive Officer (Age 50)
  • Paul W. Hoelscher, Chief Financial Officer, Executive Vice President (Age 52)
  • Barry J. Moze, Executive Vice President, Chief Administrative Officer (Age 63)
  • Brian K. Beeler, Executive Vice President, General Counsel (Age 44)
  • Robert F. Carey, Executive Vice President, Chief Business Officer (Age 58)
  • Michael A. DesJardin, Executive Vice President - Technical Operations (Age 59)
  • George P. Hampton, Executive Vice President - Primary Care Business Unit (Age 47)
  • David A. Happel, Executive Vice President - Orphan Business Unit (Age 54)
  • Jeffrey W. Sherman M.D., Executive Vice President - Research and Development and Chief Medical Officer (Age 62)
  • Vikram Karnani, Senior Vice President - Rheumatology Business Unit (Age 42)

Who owns Horizon Pharma stock?

Horizon Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.20%), William Blair Investment Management LLC (5.39%), Brandywine Global Investment Management LLC (2.54%), Glenmede Trust Co. NA (2.22%), Renaissance Technologies LLC (1.39%) and Geode Capital Management LLC (0.92%). Company insiders that own Horizon Pharma stock include Jeffrey W Sherman, Michael G Grey, Robert Carey and Virinder Nohria. View Institutional Ownership Trends for Horizon Pharma.

Who sold Horizon Pharma stock? Who is selling Horizon Pharma stock?

Horizon Pharma's stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Glenmede Trust Co. NA, Hudson Bay Capital Management LP, BlackRock Inc., Sei Investments Co., Deltec Asset Management LLC, Wells Fargo & Company MN and SG Americas Securities LLC. View Insider Buying and Selling for Horizon Pharma.

Who bought Horizon Pharma stock? Who is buying Horizon Pharma stock?

Horizon Pharma's stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, William Blair Investment Management LLC, Two Sigma Investments LP, Millennium Management LLC, Armistice Capital LLC, Cornerstone Capital Management Holdings LLC., Guggenheim Capital LLC and Brandywine Global Investment Management LLC. View Insider Buying and Selling for Horizon Pharma.

How do I buy Horizon Pharma stock?

Shares of Horizon Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Horizon Pharma's stock price today?

One share of Horizon Pharma stock can currently be purchased for approximately $13.89.

How big of a company is Horizon Pharma?

Horizon Pharma has a market capitalization of $2.28 billion and generates $981.12 million in revenue each year. The biopharmaceutical company earns $-166,830,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. Horizon Pharma employs 1,050 workers across the globe.

How can I contact Horizon Pharma?

Horizon Pharma's mailing address is Dublin 4 1st Fl 1 Burlington Road, Connaught House, DUBLIN, HM 09, Ireland. The biopharmaceutical company can be reached via phone at +353-1-7722100 or via email at [email protected]


MarketBeat Community Rating for Horizon Pharma (HZNP)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  570 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  804
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Horizon Pharma (NASDAQ:HZNP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.912.912.822.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.18$19.18$18.64$19.75
Price Target Upside: 27.12% upside27.12% upside29.87% upside50.30% upside

Horizon Pharma (NASDAQ:HZNP) Consensus Price Target History

Price Target History for Horizon Pharma (NASDAQ:HZNP)

Horizon Pharma (NASDAQ:HZNP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2018MizuhoUpgradeNeutral -> Buy$12.00 -> $18.00MediumView Rating Details
1/8/2018Cantor FitzgeraldSet Price TargetBuy$17.00MediumView Rating Details
11/7/2017Jefferies GroupBoost Price TargetBuy$16.00 -> $21.00N/AView Rating Details
10/22/2017Stifel NicolausReiterated RatingBuy$20.00N/AView Rating Details
10/15/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00N/AView Rating Details
9/28/2017CowenReiterated RatingBuyLowView Rating Details
9/28/2017Goldman Sachs GroupInitiated CoverageBuy -> Buy$16.00MediumView Rating Details
8/10/2017BMO Capital MarketsReiterated RatingOutperform$17.00 -> $18.00HighView Rating Details
5/9/2017CitigroupLower Price TargetBuy$20.00 -> $13.00MediumView Rating Details
2/28/2017Morgan StanleyReiterated RatingEqual Weight$20.00N/AView Rating Details
2/27/2017GuggenheimInitiated CoverageBuy$30.00N/AView Rating Details
9/12/2016Brean CapitalReiterated RatingBuy$32.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Horizon Pharma (NASDAQ:HZNP) Earnings History and Estimates Chart

Earnings by Quarter for Horizon Pharma (NASDAQ:HZNP)

Horizon Pharma (NASDAQ HZNP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018$0.22N/AView Earnings Details
11/6/2017Q3 2017$0.22$0.26$259.74 million$271.60 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.12$0.41$237.01 million$289.51 millionViewListenView Earnings Details
5/8/2017Q1 2017$0.25$0.21$248.71 million$220.90 millionViewListenView Earnings Details
2/27/2017Q416$0.51$0.64$307.93 million$310.30 millionViewListenView Earnings Details
11/7/2016Q316$0.63$0.70$270.04 million$273.70 millionViewListenView Earnings Details
8/8/2016Q216$0.50$0.62$235.43 million$257.40 millionViewN/AView Earnings Details
5/9/2016Q116$0.30$0.34$197.73 million$204.70 millionViewN/AView Earnings Details
2/29/2016Q415$0.62$0.63$240.92 million$244.50 millionViewListenView Earnings Details
11/6/2015Q315$0.41$0.59$185.70 million$292.70 millionViewListenView Earnings Details
8/7/2015Q215$0.32$0.39$156.41 million$172.80 millionViewListenView Earnings Details
5/8/2015Q115$0.22$0.16$104.20 million$113.10 millionViewN/AView Earnings Details
2/27/2015Q414$0.23$0.27$95.50 million$103.80 millionViewN/AView Earnings Details
11/6/2014Q314$0.19$0.24$73.17 million$75.10 millionViewN/AView Earnings Details
8/7/2014Q214$0.16$0.14$58.35 million$66.10 millionViewN/AView Earnings Details
5/9/2014Q114$0.01$0.10$42.69 million$51.90 millionViewN/AView Earnings Details
3/13/2014Q413($0.08)($0.22)$32.20 million$43.10 millionViewN/AView Earnings Details
11/8/2013Q3 13($0.25)($0.03)$18.31 million$31.50 millionViewN/AView Earnings Details
8/9/2013Q213($0.32)($0.24)$16.09 million$17.64 millionViewN/AView Earnings Details
5/10/2013Q113($0.35)($0.30)$9.47 million$9.20 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.38)ViewN/AView Earnings Details
11/13/2012Q312($0.68)($0.39)$4.12 million$7.20 millionViewN/AView Earnings Details
8/10/2012Q2 2012($0.66)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.95)ViewN/AView Earnings Details
3/23/2012Q4 2011($1.20)($3.91)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.94)($1.23)ViewN/AView Earnings Details
8/31/2011Q2 2011($6.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Horizon Pharma (NASDAQ:HZNP) Earnings Estimates

Current Year EPS Consensus Estimate: $0.72 EPS
Next Year EPS Consensus Estimate: $1.29 EPS

Dividends

Dividend History for Horizon Pharma (NASDAQ:HZNP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Horizon Pharma (NASDAQ HZNP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 84.39%
Insider Trades by Quarter for Horizon Pharma (NASDAQ:HZNP)
Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Horizon Pharma (NASDAQ HZNP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2017Michael G GreyDirectorBuy10,000$9.48$94,800.00View SEC Filing  
3/1/2017Robert CareyEVPSell31,808$16.03$509,882.24View SEC Filing  
8/2/2016Jeffrey W. ShermanEVPSell2,900$20.00$58,000.00View SEC Filing  
6/15/2016Virinder NohriaDirectorSell25,000$17.69$442,250.00189,836View SEC Filing  
2/26/2016Jeffrey W ShermanEVPSell4,100$20.00$82,000.00149,648View SEC Filing  
12/10/2015Jeffrey W ShermanEVPSell4,456$20.00$89,120.00105,132View SEC Filing  
9/21/2015Jeffrey W ShermanEVPSell7,750$31.78$246,295.00105,132View SEC Filing  
7/15/2015Jeffrey W ShermanEVPSell26,887$35.55$955,832.85View SEC Filing  
3/13/2015Jeff HimawanDirectorSell554,564$22.44$12,444,416.16View SEC Filing  
3/10/2015Jeff HimawanDirectorSell1,614,827$21.85$35,283,969.95View SEC Filing  
11/19/2014Jeff HimawanDirectorSell3,450,000$12.05$41,572,500.00View SEC Filing  
11/19/2014Jeffrey W ShermanEVPSell24,999$12.05$301,237.95View SEC Filing  
11/19/2014Timothy P WalbertCEOSell150,000$12.05$1,807,500.00View SEC Filing  
11/13/2014Balaji VenkataramanMajor ShareholderSell6,086,957$11.54$70,243,483.78View SEC Filing  
11/13/2014Virinder NohriaDirectorSell1,739,130$11.54$20,069,560.20View SEC Filing  
9/30/2014Vaere Robert J DeCFOSell51,942$12.28$637,847.76View SEC Filing  
5/19/2014Timothy WalbertCEOSell31,742$12.94$410,741.48148,930View SEC Filing  
5/19/2014Todd SmithEVPSell10,159$12.94$131,457.4644,552View SEC Filing  
5/19/2014Vaere Robert DeCFOSell12,939$12.94$167,430.6688,555View SEC Filing  
12/13/2013Jeffrey BirdDirectorBuy668,673$6.50$4,346,374.505,000View SEC Filing  
12/9/2013Timothy WalbertCEOSell12,124$6.79$82,321.96148,497View SEC Filing  
12/9/2013Todd SmithEVPSell11,322$6.91$78,235.0240,961View SEC Filing  
11/21/2013Jeffrey BirdDirectorBuy151,089$6.24$942,795.365,000View SEC Filing  
9/25/2012Jeffrey W BirdDirectorBuy575,356$3.49$2,007,992.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Horizon Pharma (NASDAQ HZNP) News Headlines

Source:
DateHeadline
Horizon Pharma PLC (HZNP) Given Average Rating of "Buy" by BrokeragesHorizon Pharma PLC (HZNP) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 13 at 11:46 AM
 Analysts Anticipate Horizon Pharma PLC (HZNP) Will Post Quarterly Sales of $267.58 Million Analysts Anticipate Horizon Pharma PLC (HZNP) Will Post Quarterly Sales of $267.58 Million
www.americanbankingnews.com - February 10 at 10:28 AM
Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Akorn, Collegium Pharma, Horizon Pharma, and ... - PR Newswire (press release)Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Akorn, Collegium Pharma, Horizon Pharma, and ... - PR Newswire (press release)
www.prnewswire.com - February 3 at 3:44 PM
Commit To Buy Horizon Pharma At $10, Earn 11.5% Using OptionsCommit To Buy Horizon Pharma At $10, Earn 11.5% Using Options
www.nasdaq.com - January 31 at 3:41 PM
Horizon Pharma plc Announces the Launch of “Cystinosis United” to Educate, Inspire and Connect the Cystinosis CommunityHorizon Pharma plc Announces the Launch of “Cystinosis United” to Educate, Inspire and Connect the Cystinosis Community
finance.yahoo.com - January 30 at 9:13 AM
Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2017 Financial Results and Host Webcast on Feb. 28, 2018Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2017 Financial Results and Host Webcast on Feb. 28, 2018
finance.yahoo.com - January 29 at 9:34 AM
Horizon Pharma (HZNP) Scheduled to Post Earnings on MondayHorizon Pharma (HZNP) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - January 29 at 4:14 AM
Financial Review: XenoPort (XNPT) and Horizon Pharma (HZNP)Financial Review: XenoPort (XNPT) and Horizon Pharma (HZNP)
www.americanbankingnews.com - January 23 at 5:06 AM
Zacks: Brokerages Anticipate Horizon Pharma PLC (HZNP) Will Announce Earnings of $0.22 Per ShareZacks: Brokerages Anticipate Horizon Pharma PLC (HZNP) Will Announce Earnings of $0.22 Per Share
www.americanbankingnews.com - January 22 at 3:26 AM
Head to Head Contrast: Amgen (AMGN) & Horizon Pharma (HZNP)Head to Head Contrast: Amgen (AMGN) & Horizon Pharma (HZNP)
www.americanbankingnews.com - January 16 at 5:08 PM
Horizon Pharma Sees Unusually Large Options Volume (HZNP)Horizon Pharma Sees Unusually Large Options Volume (HZNP)
www.americanbankingnews.com - January 13 at 3:15 AM
Horizon Pharma (HZNP) Upgraded to "Buy" by MizuhoHorizon Pharma (HZNP) Upgraded to "Buy" by Mizuho
www.americanbankingnews.com - January 12 at 8:02 AM
Horizon Pharma (HZNP) Increases Peak Net Sales Guidance, Announces Rheumatology and Orphan Pipeline ... - StreetInsider.comHorizon Pharma (HZNP) Increases Peak Net Sales Guidance, Announces Rheumatology and Orphan Pipeline ... - StreetInsider.com
www.streetinsider.com - January 9 at 7:17 AM
Horizon Pharma plc Announces Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmune - GlobeNewswire (press release)Horizon Pharma plc Announces Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmune - GlobeNewswire (press release)
globenewswire.com - January 8 at 3:24 PM
Horizon Pharma (HZNP) PT Set at $17.00 by Cantor FitzgeraldHorizon Pharma (HZNP) PT Set at $17.00 by Cantor Fitzgerald
www.americanbankingnews.com - January 8 at 11:50 AM
Horizon Pharma plc Announces Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmuneHorizon Pharma plc Announces Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmune
finance.yahoo.com - January 8 at 11:13 AM
What Does Horizon Pharma Public Limited Company’s (NASDAQ:HZNP) Share Price Indicate?What Does Horizon Pharma Public Limited Company’s (NASDAQ:HZNP) Share Price Indicate?
finance.yahoo.com - January 8 at 11:13 AM
Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline DevelopmentsHorizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments
finance.yahoo.com - January 8 at 11:13 AM
$267.58 Million in Sales Expected for Horizon Pharma PLC (HZNP) This Quarter$267.58 Million in Sales Expected for Horizon Pharma PLC (HZNP) This Quarter
www.americanbankingnews.com - January 7 at 1:52 PM
Horizon Pharma plc Reports Inducement Grants Under NASDAQ ... - GlobeNewswire (press release)Horizon Pharma plc Reports Inducement Grants Under NASDAQ ... - GlobeNewswire (press release)
globenewswire.com - January 6 at 7:36 AM
Horizon Pharma (HZNP) PT Raised to $18 at Citi on 2018 Outlook ... - StreetInsider.comHorizon Pharma (HZNP) PT Raised to $18 at Citi on 2018 Outlook ... - StreetInsider.com
www.streetinsider.com - January 5 at 6:40 AM
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
globenewswire.com - January 5 at 6:40 AM
Horizon Pharma PLC (HZNP) Expected to Post Earnings of $0.22 Per ShareHorizon Pharma PLC (HZNP) Expected to Post Earnings of $0.22 Per Share
www.americanbankingnews.com - January 5 at 5:30 AM
Stifel Has 5 Specialty Pharmaceutical 2018 Buys With Massive Upside PotentialStifel Has 5 Specialty Pharmaceutical 2018 Buys With Massive Upside Potential
247wallst.com - January 4 at 3:20 PM
Horizon Pharma (HZNP) Lowered to Hold at ValuEngineHorizon Pharma (HZNP) Lowered to Hold at ValuEngine
www.americanbankingnews.com - January 1 at 10:28 PM
3 Top Value Stocks to Buy in 2018 - Motley Fool3 Top Value Stocks to Buy in 2018 - Motley Fool
www.fool.com - December 31 at 3:21 PM
Horizon Pharma Gets FDA Nod for Procysbi Label Expansion - NasdaqHorizon Pharma Gets FDA Nod for Procysbi Label Expansion - Nasdaq
www.nasdaq.com - December 30 at 7:16 AM
Horizon Pharma plc Announces FDA Approval to Expand the Indication for ...Horizon Pharma plc Announces FDA Approval to Expand the Indication for ...
www.nasdaq.com - December 28 at 4:30 PM
Horizon Pharma (HZNP) PROCYSBI Approved by FDA for Expanded IndicationHorizon Pharma (HZNP) PROCYSBI Approved by FDA for Expanded Indication
www.streetinsider.com - December 28 at 4:30 PM
Horizon Pharma Gets FDA Nod for Procysbi Label ExpansionHorizon Pharma Gets FDA Nod for Procysbi Label Expansion
finance.yahoo.com - December 28 at 4:30 PM
Horizon Pharma (HZNP) PROCYSBI Approved by FDA for Expanded Indication - StreetInsider.comHorizon Pharma (HZNP) PROCYSBI Approved by FDA for Expanded Indication - StreetInsider.com
www.streetinsider.com - December 27 at 8:12 PM
Horizon Pharma (HZNP) Given a $17.00 Price Target at Cantor FitzgeraldHorizon Pharma (HZNP) Given a $17.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - December 27 at 3:16 PM
Horizon Pharma Shows Improved Relative Price Performance; Still Shy Of BenchmarkHorizon Pharma Shows Improved Relative Price Performance; Still Shy Of Benchmark
finance.yahoo.com - December 27 at 3:08 PM
ETFs with exposure to Horizon Pharma Plc : December 27, 2017ETFs with exposure to Horizon Pharma Plc : December 27, 2017
finance.yahoo.com - December 27 at 3:08 PM
Horizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic CystinosisHorizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic Cystinosis
finance.yahoo.com - December 27 at 9:57 AM
Horizon Pharma shares jump 3% premarket after FDA expands use of treatment for metabolic disorderHorizon Pharma shares jump 3% premarket after FDA expands use of treatment for metabolic disorder
finance.yahoo.com - December 27 at 9:57 AM
Horizon Pharma PLC (HZNP) Given Consensus Recommendation of "Buy" by BrokeragesHorizon Pharma PLC (HZNP) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 25 at 11:04 AM
Horizon Pharma (HZNP) Stock Rating Upgraded by BidaskClubHorizon Pharma (HZNP) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 23 at 2:10 PM
Zacks: Analysts Anticipate Horizon Pharma PLC (HZNP) Will Announce Quarterly Sales of $267.58 MillionZacks: Analysts Anticipate Horizon Pharma PLC (HZNP) Will Announce Quarterly Sales of $267.58 Million
www.americanbankingnews.com - December 21 at 4:26 AM
Horizon Pharma: Primary Care Segment Remains A Burden And ... - Seeking AlphaHorizon Pharma: Primary Care Segment Remains A Burden And ... - Seeking Alpha
seekingalpha.com - December 20 at 6:33 AM
Horizon Pharma (HZNP) PT Raised to $19 at Goldman Sachs Following Management Meetings; Entering Next Phase ... - StreetInsider.comHorizon Pharma (HZNP) PT Raised to $19 at Goldman Sachs Following Management Meetings; 'Entering Next Phase ... - StreetInsider.com
www.streetinsider.com - December 19 at 7:09 AM
Horizon Pharma plc to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)Horizon Pharma plc to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - December 19 at 7:09 AM
Free Research Report as Horizon Pharma’s Revenue Grew 30.2%Free Research Report as Horizon Pharma’s Revenue Grew 30.2%
finance.yahoo.com - December 18 at 3:20 PM
Head to Head Survey: Horizon Pharma (HZNP) & Akorn (AKRX)Head to Head Survey: Horizon Pharma (HZNP) & Akorn (AKRX)
www.americanbankingnews.com - December 17 at 1:50 PM
Stocks With Rising Relative Price Strength: Horizon PharmaStocks With Rising Relative Price Strength: Horizon Pharma
finance.yahoo.com - December 15 at 3:21 PM
Technical Perspectives on Horizon Pharma, Akari Therapeutics, MYOS RENS Technology, and Zynerba Pharma - PR Newswire (press release)Technical Perspectives on Horizon Pharma, Akari Therapeutics, MYOS RENS Technology, and Zynerba Pharma - PR Newswire (press release)
www.prnewswire.com - December 15 at 6:32 AM
Horizon Pharma Earns RS Rating UpgradeHorizon Pharma Earns RS Rating Upgrade
finance.yahoo.com - December 14 at 3:21 PM
ETFs with exposure to Horizon Pharma Plc : December 4, 2017ETFs with exposure to Horizon Pharma Plc : December 4, 2017
finance.yahoo.com - December 4 at 3:19 PM
 Brokerages Expect Horizon Pharma PLC (HZNP) to Announce $0.22 Earnings Per Share Brokerages Expect Horizon Pharma PLC (HZNP) to Announce $0.22 Earnings Per Share
www.americanbankingnews.com - December 1 at 11:34 PM
Horizon Pharma (HZNP) Given a $17.00 Price Target by Cantor Fitzgerald AnalystsHorizon Pharma (HZNP) Given a $17.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - December 1 at 4:12 PM

SEC Filings

Horizon Pharma (NASDAQ:HZNP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Horizon Pharma (NASDAQ:HZNP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Horizon Pharma (NASDAQ HZNP) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.